Does Afirma Molecular Testing Reduce Surgery Rates and Improve Management Appropriateness in Bethesda III–IV Thyroid Nodules?. // Journal of the American Society of Cytopathology. – URL: https://www.sciencedirect.com/science/article/pii/S2213294526002152?dgcid=rss_sd_all
Does Afirma Molecular Testing Reduce Surgery Rates and Improve Management Appropriateness in Bethesda III–IV Thyroid Nodules?. Journal of the American Society of Cytopathology. https://www.sciencedirect.com/science/article/pii/S2213294526002152?dgcid=rss_sd_all
“Does Afirma Molecular Testing Reduce Surgery Rates and Improve Management Appropriateness in Bethesda III–IV Thyroid Nodules?.” Journal of the American Society of Cytopathology.
@article{article31316,
title = {Does Afirma Molecular Testing Reduce Surgery Rates and Improve Management Appropriateness in Bethesda III–IV Thyroid Nodules?},
journal = {Journal of the American Society of Cytopathology},
url = {https://www.sciencedirect.com/science/article/pii/S2213294526002152?dgcid=rss_sd_all}
}
ABSTRACT High‐dimensional flow cytometry measures immune cells at single‐cell resolution, enabling systematic characterization of cell populations at scale. But harnessing this potential requires seamless interoperability between the...
Abstract The intraneuronal accumulation of amyloid‐β (Aβ) is an early pathogenic event in Alzheimer's disease (AD), initiating a pathological cascade that includes synaptic dysfunction, metabolic deficits, and eventual neuronal loss....